CoChat

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

Cowin, Prue A., George, Joshy, Fereday, Sian, Loehrer, Elizabeth, Van Loo, Peter, Cullinane, Carleen, Etemadmoghadam, Dariush, Ftouni, Sarah, Galletta, Laura, Anglesio, Michael S., Hendley, Joy, Bowes, Leanne, Sheppard, Karen E., Christie, Elizabeth L., Australian Ovarian Cancer Study, Pearson, Richard B., Harnett, Paul R., Heinzelmann-Schwarz, Viola, Friedlander, Michael, McNally, Orla, Quinn, Michael, Campbell, Peter, deFazio, Anna, Bowtell, David D.L. · 2012 · Cancer Research
Cited by 109

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

High-grade serous cancer (HGSC), the most common subtype of ovarian cancer, often becomes resistant to chemotherapy, leading to poor patient outcomes. Intratumoral heterogeneity occurs in nearly all solid cancers, including ovarian cancer, contributing to the development of resistance mechanisms. In this study, we examined the spatial and temporal genomic variation in HGSC using high-resolution single-nucleotide polymorphism arrays. Multiple metastatic lesions from individual patients were analyzed along with 22 paired pretreatment and posttreatment samples. We documented regions of differential DNA copy number between multiple tumor biopsies that correlated with altered expression of genes involved in cell polarity and adhesion. In the paired primary and relapse cohort, we observed a greater degree of genomic change in tumors from patients that were initially sensitive to chemotherapy and had longer progression-free interval compared with tumors from patients that were resistant to primary chemotherapy. Notably, deletion or downregulation of the lipid transporter LRP1B emerged as a significant correlate of acquired resistance in our analysis. Functional studies showed that reducing LRP1B expression was sufficient to reduce the sensitivity of HGSC cell lines to liposomal doxorubicin, but not to doxorubicin, whereas LRP1B overexpression was sufficient to increase sensitivity to liposomal doxorubicin. Together, our findings underscore the large degree of variation in DNA copy number in spatially and temporally separated tumors in HGSC patients, and they define LRP1B as a potential contributor to the emergence of chemotherapy resistance in these patients. Cancer Res; 72(16); 4060–73. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-0203

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 109

Metadata

Authors
Cowin, P. A., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., Hendley, J., Bowes, L., Sheppard, K. E., Christie, E. L., Study, A. O. C., Pearson, R. B., Harnett, P. R., Heinzelmann-Schwarz, V., Friedlander, M., McNally, O., Quinn, M., Campbell, P., deFazio, A., & Bowtell, D. D. L.
Venue
Cancer Research
Published
2012-08-14
Volume
72
Issue
16
Pages
4060-4073
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2034655041
Cited by
109
References
9
FWCI
7.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-0203
The paper
Cowin, P. A., George, J., Fereday, S., Loehrer, E., Van Loo, P., Cullinane, C., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., Hendley, J., Bowes, L., Sheppard, K. E., Christie, E. L., Study, A. O. C., Pearson, R. B., Harnett, P. R., Heinzelmann-Schwarz, V., Friedlander, M., . . . Bowtell, D. D. L. (2012). LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-0203

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.